A Mechanism Study of DUSP1 in Inhibiting Malignant Progression of Endometrial Carcinoma by Regulating ERK/AP-1 Axis and Dephosphorylation of EPHA2

Overview

Journal J Cancer

Specialty Oncology

Date 2023 Apr 14

PMID 37057290

Authors

Shu Lei

Xiangjun He

Xiao Yang

Xuan Gu

Yijiao He

Jianliu Wang

Affiliations

Soon will be listed here.

Abstract

Endometrial carcinoma is one of the most common female malignancies worldwide. Based on our preliminary investigation, DUSP1 was identified as a potential biomarker for endometrial carcinoma prognosis, but its function and mechanism remained unclear. In this study, genes highly correlated with DUSP1 in endometrial cancer were found through correlation analysis, and the promoter sequence of DUSP1 was analyzed by PROMO program. Next-generation phosphorylation mass spectrometry was used to explore new downstream target proteins and pathways of DUSP1 in endometrial carcinoma. The mRNA and protein expression levels were detected by real-time quantitative PCR, immunohistochemistry and Western blotting. The cell survival and proliferation were analyzed by CCK8 assay, cell apoptosis was analyzed by Annexin-V-APC and PI dual staining assay, and the cell invasion was analyzed by Transwell method. (1) There was a high correlation between the expression of DUSP1 and the genes involved in AP-1 complex and its co-expression network. (2) Promoter sequence analysis predicted that the members of AP-1 complex might be the upstream transcriptional regulators of DUSP1. (3) Transfection experiments proved DUSP1 can inhibit tumor growth and invasion, and promote apoptosis by regulating ERK pathway. (4) The results of phosphorylation mass spectrometry showed that overexpression of DUSP1 mainly dephosphorylated EPHA2 in endometrial carcinoma, and co-immunoprecipitation verified the protein interaction between DUSP1 and EPHA2. (5) Overexpression or knockdown of EPHA2 significantly changed the phosphorylation level of EPHA2. (6) The expression of EPHA2 protein was high in patients with more aggressive endometrial cancer. (7) Using EPHA2 inhibitor could significantly slow down the growth rate of tumor cells. (1) There exists a mutual regulation relationship between DUSP1 and AP-1 co-expression network in endometrial carcinoma. (2) It is reported for the first time that DUSP1 phosphatase acts on the ser899 site of EphA2 in endometrial carcinoma. (3) DUSP1 can inhibit tumor growth and invasion, and promote apoptosis by regulating MAPK pathway through directly dephosphorylating ERK, or by dephosphorylating EPHA2.

Citing Articles

Upregulation of hsa-miR-141-3p promotes uterine cervical carcinoma progression via targeting dual-specificity protein phosphatase 1.

Liang Z, Zhang W, Zeng D, Chen J, Luo J, Shi L Funct Integr Genomics. 2024; 24(4):137.

PMID: 39138666 DOI: 10.1007/s10142-024-01413-z.

Early growth response 1 regulates dual‑specificity protein phosphatase 1 and inhibits cell migration and invasion of tongue squamous cell carcinoma.

Zhou L, Shan Y, Li J, Li M, Meng Z, Guo N Oncol Lett. 2024; 27(6):240.

PMID: 38623570 PMC: 11017821. DOI: 10.3892/ol.2024.14373.

References

Bokhman J . Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1):10-7. DOI: 10.1016/0090-8258(83)90111-7. View

Kesarwani M, Kincaid Z, Gomaa A, Huber E, Rohrabaugh S, Siddiqui Z . Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. Nat Med. 2017; 23(4):472-482. PMC: 5424814. DOI: 10.1038/nm.4310. View

Treinies I, PATERSON H, Hooper S, Wilson R, Marshall C . Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. Mol Cell Biol. 1998; 19(1):321-9. PMC: 83890. DOI: 10.1128/MCB.19.1.321. View

Xiao T, Xiao Y, Wang W, Tang Y, Xiao Z, Su M . Targeting EphA2 in cancer. J Hematol Oncol. 2020; 13(1):114. PMC: 7433191. DOI: 10.1186/s13045-020-00944-9. View

Mechta F, lAllemand D, Pfarr C, Yaniv M . Transformation by ras modifies AP1 composition and activity. Oncogene. 1997; 14(7):837-47. DOI: 10.1038/sj.onc.1200900. View

Du Y, Lu S, Ge J, Long D, Wen C, Tan S . ROCK2 disturbs MKP1 expression to promote invasion and metastasis in hepatocellular carcinoma. Am J Cancer Res. 2020; 10(3):884-896. PMC: 7136912. View

Leelahavanichkul K, Amornphimoltham P, Molinolo A, Basile J, Koontongkaew S, Gutkind J . A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis. Mol Oncol. 2013; 8(1):105-18. PMC: 3946852. DOI: 10.1016/j.molonc.2013.10.003. View

Camps M, Nichols A, Arkinstall S . Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 2000; 14(1):6-16. View

Fedorov Y, Anderson E, Birmingham A, Reynolds A, Karpilow J, Robinson K . Off-target effects by siRNA can induce toxic phenotype. RNA. 2006; 12(7):1188-96. PMC: 1484448. DOI: 10.1261/rna.28106. View

10.

Westwick J, Cox A, Der C, Cobb M, Hibi M, Karin M . Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases. Proc Natl Acad Sci U S A. 1994; 91(13):6030-4. PMC: 44131. DOI: 10.1073/pnas.91.13.6030. View

11.

Goddio M, Gattelli A, Slomiansky V, Lacunza E, Gingerich T, Tocci J . Mammary differentiation induces expression of Tristetraprolin, a tumor suppressor AU-rich mRNA-binding protein. Breast Cancer Res Treat. 2012; 135(3):749-58. DOI: 10.1007/s10549-012-2216-0. View

12.

Moncho-Amor V, Ibanez de Caceres I, Bandres E, Martinez-Poveda B, Orgaz J, Sanchez-Perez I . DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer. Oncogene. 2010; 30(6):668-78. DOI: 10.1038/onc.2010.449. View

13.

Liao Q, Guo J, Kleeff J, Zimmermann A, Buchler M, Korc M . Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology. 2003; 124(7):1830-45. DOI: 10.1016/s0016-5085(03)00398-6. View

14.

Katagiri T, Kameda H, Nakano H, Yamazaki S . Regulation of T cell differentiation by the AP-1 transcription factor JunB. Immunol Med. 2021; 44(3):197-203. DOI: 10.1080/25785826.2021.1872838. View

15.

Canzoneri R, Naipauer J, Stedile M, Rodriguez Pena A, Lacunza E, Gandini N . Identification of an AP1-ZFP36 Regulatory Network Associated with Breast Cancer Prognosis. J Mammary Gland Biol Neoplasia. 2020; 25(2):163-172. DOI: 10.1007/s10911-020-09448-1. View

16.

Abdulfatah E, Ahmed Q, Alosh B, Bandyopadhyay S, Bluth M, Ali-Fehmi R . Gynecologic Cancers: Molecular Updates 2018. Clin Lab Med. 2018; 38(2):421-438. DOI: 10.1016/j.cll.2018.02.007. View

17.

Shim K, Lee S, Ryu S, Min Y, Kim S . Corosolic acid stimulates osteoblast differentiation by activating transcription factors and MAP kinases. Phytother Res. 2009; 23(12):1754-8. DOI: 10.1002/ptr.2843. View

18.

Eferl R, Wagner E . AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003; 3(11):859-68. DOI: 10.1038/nrc1209. View

19.

Karin M, Liu Z, Zandi E . AP-1 function and regulation. Curr Opin Cell Biol. 1997; 9(2):240-6. DOI: 10.1016/s0955-0674(97)80068-3. View

20.

Huang C, Tan T . DUSPs, to MAP kinases and beyond. Cell Biosci. 2012; 2(1):24. PMC: 3406950. DOI: 10.1186/2045-3701-2-24. View